Shashi Husain, MD
Payments from drug & device makers
Across 95 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$331
- AbbVie$204
- Novartis$148
- Biogen$109
- UCB, Inc.$77
- Supernus Pharmaceuticals, Inc.$72
- plus $788 from 24 others
What the payments were for
- Food & beverage$1,69998%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 15 | $331 |
| AbbVie(2 entities) | 18 | $204 |
| Novartis | 7 | $148 |
| Biogen | 6 | $109 |
| UCB, Inc. | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 4 | $72 |
| Genentech USA, Inc. | 3 | $64 |
| Eisai Inc. | 4 | $62 |
| Pfizer | 3 | $56 |
| Amneal Pharmaceuticals LLC | 3 | $54 |
| Acadia Pharmaceuticals Inc | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Avion Pharmaceuticals | 2 | $43 |
| Lilly USA, LLC | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Lundbeck LLC | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| EMD Serono, Inc. | 2 | $28 |
| GE HealthCare | 1 | $26 |
| Adamas Pharmaceuticals, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Merz North America, Inc. | 1 | $22 |
| Sanofi | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Boston Scientific | 1 | $11 |
How this compares
$1,729 in reported general payments places this provider in the 50th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 108 | $132,490 |
| IngrezzaValbenazine Tosylate | 15 | $112,412 |
| XcopriCenobamate | 38 | $59,005 |
| BriviactBrivaracetam | 23 | $37,325 |
| BotoxOnabotulinumtoxina | 25 | $32,710 |
| FycompaPerampanel | 24 | $26,576 |
| Emgality PenGalcanezumab-Gnlm | 14 | $14,990 |
| NamzaricMemantine Hcl/Donepezil Hcl | 21 | $11,937 |
| NeuproRotigotine | 13 | $11,035 |
| Gabapentin | 297 | $3,878 |
| Lamotrigine | 270 | $3,107 |
| Levetiracetam | 114 | $2,389 |
| Baclofen | 162 | $2,303 |
| Primidone | 148 | $2,155 |
| Carbamazepine ErCarbamazepine | 27 | $2,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Botox, Namzaric | $204 | $177,136154 claims |
| SK Life Science, Inc.Xcopri | $331 | $59,00538 claims |
| UCB, Inc.Briviact, Neupro | $77 | $48,36036 claims |
| Eisai Inc.Fycompa | $62 | $26,57624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 152 neurology providers in Oklahoma.
Other neurology in Tulsa
- Michael KarathanosTulsa$4.4M
- Aimee BorazanciTulsa$1.9M
- Jaclyn DuvallTulsa$1.4M
- Tania ReynaTulsa$950K
- Ralph RichterTulsa$492K
- Gregory ConnorTulsa$447K
- Christopher GlissonTulsa$125K
- Alok PasrichaTulsa$81K
- Randall WebbTulsa$36K
- Todd DunawayTulsa$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.